Table 1.

NNRTI mutations detected by population sequencing and AS-PCR among 255 sdNVP-exposed children initiating antiretroviral therapy.

	0-6 months	6-12 months	12-18 months	18-24 months	Total	p-value**
	N=81	N=97	N=45	N=32	N=255
Mutation detection
Total N (%) with detectable major NNRTI mutations:
By population sequencing	37 (45.7%)	23 (23.7%)	9 (20.0%)	0	69 (27.1%)	<0.0001
By AS-PCR only	13 (16.0%)	14 (14.4%)	1 (2.2%)	5 (15.6%)	34 (12.9%)	0.13
N (%) with detectable Y181C:
By population sequencing	25 (30.9%)	20 (20.6%)	7 (15.6%)	0	52 (20.4%)	0.0025
By AS-PCR only*	10 (12.5%)	11 (11.8%)	1 (2.2%)	3 (9.4%)	25 (10.0%)	0.27
N (%) with detectable K103N:
By population sequencing	10 (12.3%)	1 (1.0%)	2 (4.4%)	0	13 (5.1%)	0.0031
By AS-PCR only	16 (19.8%)	3 (3.1%)	0	2 (6.3%)	21 (8.2%)	<0.0001
N (%) with other major NNRTI mutations
V106IM	0	1 (1.0%)	0	0	1 (0.4%)	0.65
Y188C	1 (1.2%)	1 (1.0%)	0	0	2 (0.8%)	0.83
G190A	2 (2.5%)	0	0	0	2 (0.8%)	0.23
N (%) with minor NNRTI mutations:
V90I	2 (2.5%)	0	1 (2.2%)	0	3 (1.2%)	0.37
A98G	0	1 (1.0%)	0	0	1 (0.4%)	0.65
E138A	8 (9.9%)	5 (5.2%)	6 (13.3%)	1 (3.1%)	20 (7.8%)	0.23
V179D	1 (1.2%)	4 (5.1%)	2 (4.4%)	0	7 (2.7%)	0.43

^*One child aged 0-6 months and 4 children aged 6-12 month were excluded from analyses due to indeterminate Y181C AS-PCR results.

^**P-values determined by comparing percentage of positive samples in each age category (Chi-squared test for trend)